File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Efficacy of Janus kinase inhibitors or biologic disease-modifying antirheumatic drugs in psoriatic arthritis patients: a network meta-analysis

TitleEfficacy of Janus kinase inhibitors or biologic disease-modifying antirheumatic drugs in psoriatic arthritis patients: a network meta-analysis
Authors
Issue Date2020
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/
Citation
The 25th Annual Medical Research Conference, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, 18 January 2020. In Hong Kong Medical Journal, 2020, v. 26 n. 1, Suppl. 1, p. 31, abstract no. 50 How to Cite?
AbstractIntroduction: Novel therapeutic agents, which include Janus kinase inhibitors and biologic disease-modifying antirheumatic drugs, are more efficacious than placebo in psoriatic arthritis (PsA) patients. However, there were limited studies to compare efficacy between different novel therapeutic agents. Methods: We searched for randomised controlled trials using ISI Web of Science, Scopus, Medline, Cochrane library, Clinicaltrials.gov, and Embase. Studies reporting the proportion of PsA patients that achieved ACR20 response were included. They were stratified into two groups: (1) biologic-naïve; and (2) intolerant to tumour necrosis factor inhibitor (TNFi). Results were analysed using R version 3.6.1 with “netmeta” version 1.1-0. Odds ratio (OR) and 95% confidence interval (CI) were estimated using random-effects model. P-rank scores were used to estimate the best therapeutic option for a specific group of PsA patients. Results: In this network meta-analysis, 31 studies were included; 29 were in biologic-naïve and nine were in TNFi-intolerant populations. Golimumab was the best option in biologic-naïve patients (P-rank score 0.9324), superior to abatacept (OR [95% CI]=0.14 [0.06-0.36]), adalimumab (0.33 [0.18-0.62]), apremilast (0.21 [0.11-0.38]), certolizumab (0.40 [0.17-0.94]), guselkumab (0.39 [0.20-0.76]), ixekizumab (0.33 [0.16-0.66]), tofacitinib (0.30 [0.14-0.66]), and ustekinumab (0.28 [0.14-0.56]). However, golimumab was not significantly more efficacious than etanercept (0.94 [0.39-2.22]), filgotinib (0.62 [0.21-1.82]), and secukinumab (0.57 [0.30-1.06]). Apremilast was the best option in TNFi-intolerant patients (P-rank score: 0.8479), but there were no significant differences in efficacy between apremilast and other therapeutic agents. Conclusions: All novel therapeutic agents show similar efficacy in PsA patients with TNFi failure. Golimumab is more efficacious than abatacept, adalimumab, apremilast, guselkumab, ixekizumab, tofacitinib, and ustekinumab in biologic-naïve patients.
Persistent Identifierhttp://hdl.handle.net/10722/281728
ISSN
2023 Impact Factor: 3.1
2023 SCImago Journal Rankings: 0.261

 

DC FieldValueLanguage
dc.contributor.authorTsoi, MF-
dc.contributor.authorFei, Y-
dc.contributor.authorCheung, BMY-
dc.contributor.authorLau, WCS-
dc.contributor.authorCheung, TT-
dc.date.accessioned2020-03-22T04:18:49Z-
dc.date.available2020-03-22T04:18:49Z-
dc.date.issued2020-
dc.identifier.citationThe 25th Annual Medical Research Conference, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, 18 January 2020. In Hong Kong Medical Journal, 2020, v. 26 n. 1, Suppl. 1, p. 31, abstract no. 50-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/281728-
dc.description.abstractIntroduction: Novel therapeutic agents, which include Janus kinase inhibitors and biologic disease-modifying antirheumatic drugs, are more efficacious than placebo in psoriatic arthritis (PsA) patients. However, there were limited studies to compare efficacy between different novel therapeutic agents. Methods: We searched for randomised controlled trials using ISI Web of Science, Scopus, Medline, Cochrane library, Clinicaltrials.gov, and Embase. Studies reporting the proportion of PsA patients that achieved ACR20 response were included. They were stratified into two groups: (1) biologic-naïve; and (2) intolerant to tumour necrosis factor inhibitor (TNFi). Results were analysed using R version 3.6.1 with “netmeta” version 1.1-0. Odds ratio (OR) and 95% confidence interval (CI) were estimated using random-effects model. P-rank scores were used to estimate the best therapeutic option for a specific group of PsA patients. Results: In this network meta-analysis, 31 studies were included; 29 were in biologic-naïve and nine were in TNFi-intolerant populations. Golimumab was the best option in biologic-naïve patients (P-rank score 0.9324), superior to abatacept (OR [95% CI]=0.14 [0.06-0.36]), adalimumab (0.33 [0.18-0.62]), apremilast (0.21 [0.11-0.38]), certolizumab (0.40 [0.17-0.94]), guselkumab (0.39 [0.20-0.76]), ixekizumab (0.33 [0.16-0.66]), tofacitinib (0.30 [0.14-0.66]), and ustekinumab (0.28 [0.14-0.56]). However, golimumab was not significantly more efficacious than etanercept (0.94 [0.39-2.22]), filgotinib (0.62 [0.21-1.82]), and secukinumab (0.57 [0.30-1.06]). Apremilast was the best option in TNFi-intolerant patients (P-rank score: 0.8479), but there were no significant differences in efficacy between apremilast and other therapeutic agents. Conclusions: All novel therapeutic agents show similar efficacy in PsA patients with TNFi failure. Golimumab is more efficacious than abatacept, adalimumab, apremilast, guselkumab, ixekizumab, tofacitinib, and ustekinumab in biologic-naïve patients.-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/-
dc.relation.ispartofHong Kong Medical Journal-
dc.relation.ispartof25th Medical Research Conference-
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.-
dc.titleEfficacy of Janus kinase inhibitors or biologic disease-modifying antirheumatic drugs in psoriatic arthritis patients: a network meta-analysis-
dc.typeConference_Paper-
dc.identifier.emailTsoi, MF: smftsoi@hku.hk-
dc.identifier.emailCheung, BMY: mycheung@hkucc.hku.hk-
dc.identifier.emailLau, WCS: cslau@hku.hk-
dc.identifier.emailCheung, TT: tcheungt@hku.hk-
dc.identifier.authorityCheung, BMY=rp01321-
dc.identifier.authorityLau, WCS=rp01348-
dc.identifier.authorityCheung, TT=rp01682-
dc.identifier.hkuros309416-
dc.identifier.volume26-
dc.identifier.issue1, Suppl. 1-
dc.identifier.spage31, abstract no. 50-
dc.identifier.epage31, abstract no. 50-
dc.publisher.placeHong Kong-
dc.identifier.issnl1024-2708-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats